NU-AZATHIOPRINE TABLET

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

AZATHIOPRINE

Διαθέσιμο από:

NU-PHARM INC

Φαρμακολογική κατηγορία (ATC):

L04AX01

INN (Διεθνής Όνομα):

AZATHIOPRINE

Δοσολογία:

50MG

Φαρμακοτεχνική μορφή:

TABLET

Σύνθεση:

AZATHIOPRINE 50MG

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

100

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

IMMUNOSUPPRESSIVE AGENTS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0101830001; AHFS:

Καθεστώς αδειοδότησης:

CANCELLED (UNRETURNED ANNUAL)

Ημερομηνία της άδειας:

2018-03-28

Αρχείο Π.Χ.Π.

1
PRODUCT MONOGRAPH
NU-AZATHIOPRINE
AZATHIOPRINE TABLETS USP
50 MG
IMMUNOSUPPRESSIVE AGENT
NU-PHARM INC.
DATE OF PREPARATION:
50 MURAL STREET UNITS 1 & 2
January 12, 2004
RICHMOND HILL, ONTARIO
L4B 1E4
_Control #: 089003_
2
PRODUCT MONOGRAPH
NU-AZATHIOPRINE
Azathioprine Tablets USP
50 mg
THERAPEUTIC CLASSIFICATION
Immunosuppressive Agent
ACTIONS AND CLINICAL PHARMACOLOGY
METABOLISM
Azathioprine is well absorbed following oral administration. Maximum
serum radioactivity
occurs at one to two hours after oral
35
S-azathioprine and decays with a half-life of five hours.
This is not an estimate of the half-life of azathioprine itself but is
the decay rate for all
35
S-
containing metabolites of the drug. Because of extensive metabolism,
only a fraction of the
radioactivity is present as azathioprine. Usual doses produce blood
levels of azathioprine, and
of mercaptopurine derived from it, which are low (<1
:
g/mL). Blood levels are of little predictive
value for therapy since the magnitude and duration of clinical effects
correlate with thiopurine
nucleotide levels in tissues rather than with plasma drug levels.
Azathioprine and
mercaptopurine are moderately bound to serum proteins (30%) and are
partially dialyzable.
Azathioprine is cleaved _in vivo_ to mercaptopurine. Both compounds
are rapidly eliminated from
blood and are oxidized or methylated in erythrocytes and liver; no
azathioprine or
mercaptopurine is detectable in urine after eight hours. Conversion to
inactive 6-thiouric acid by
xanthine oxidase is an important degradative pathway, and the
inhibition of this pathway in
patients receiving Zyloprim® (allopurinol) is the basis for the
azathioprine dosage reduction
required in these patients (see Drug Interactions under PRECAUTIONS).
Proportions of
metabolites are different in individual patients, and this presumably
accounts for variable
magnitude and duration of drug effects. Renal clearance is probably
not important in predicting
biological effectiveness or toxicities, although dose reduction is
practised in